Johnson & Johnson will issue a report in February giving the average increase in the list prices for all company drugs in the United States, as well as their average price after the discounts given by the company.
The report will also show that Johnson & Johnson about two-thirds of its sales growth comes from selling more drugs, rather than raising their prices and finally It clear out that it spends more on research than marketing,
The company hopes the report will helping address public concerns about aggressive price increases.
However Johnson & Johnson has announced that it will provide only an average across all the company’s drugs
Source: The Wall Street Journal